Skip to content
DataLookout
Menu

National Cancer Institute (NCI) clinical trial pipeline

Get alerts when National Cancer Institute (NCI)'s trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-22

What changed in the last 30 days

85 trials changed in the last 30 days: 1 stopped, 27 with notable changes, 57 with minor changes only.

  1. Minor: Immunotherapy After Surgery · No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial Trial sites expanded: 284 → 287 locations National Cancer Institute (NCI)Phase 3 NCT06498635
  2. Minor: Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial Trial sites expanded: 148 → 171 locations National Cancer Institute (NCI)Phase 3 NCT07388524
  3. Minor: Different Treatment Lengths for Venetoclax · Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Trial sites expanded: 69 → 83 locations National Cancer Institute (NCI)Phase 2 NCT07437950
  4. Notable: MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027 National Cancer Institute (NCI)Phase 2 NCT06390865
  5. Notable: MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027 National Cancer Institute (NCI)Phase 2 NCT06385496
  6. Notable: Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers Start date pushed from Nov 23, 2026 to Jan 19, 2027 National Cancer Institute (NCI)Phase 2 NCT07686367
  7. Minor: Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness Enrollment closed, study ongoing National Cancer Institute (NCI)Phase 1/2 NCT05691491
  8. Notable: Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study Enrollment increased: 1 → 946 participants National Cancer Institute (NCI)Not specified NCT03309033
  9. Minor: Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib · High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial Trial sites expanded: 258 → 262 locations National Cancer Institute (NCI)Phase 3 NCT07391774
  10. Minor: Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer · a Weakened Immune System Trial sites expanded: 57 → 60 locations National Cancer Institute (NCI)Phase 2 NCT07042295
  11. Minor: Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Trial sites expanded: 22 → 27 locations National Cancer Institute (NCI)Phase 2 NCT07504588
  12. Minor: Experimental Approach · Plasma Cell Leukemia, The QUANTUM Trial Trial sites expanded: 11 → 14 locations National Cancer Institute (NCI)Phase 2 NCT07605416
  13. Minor: Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) Trial sites expanded: 149 → 152 locations National Cancer Institute (NCI)Phase 2 NCT06577441
  14. Minor: Vanguard Study: Testing a New Way to Screen for Cancer Trial sites expanded: 44 → 49 locations National Cancer Institute (NCI)Not applicable NCT06995898
  15. Minor: Methoxyamine, Cisplatin, and Pemetrexed Disodium · Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Study completion pushed from Oct 15, 2026 to Oct 15, 2027 National Cancer Institute (NCI)Phase 1/2 NCT02535312
  16. Notable: Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial Results posted: Nov 17, 2026 National Cancer Institute (NCI)Phase 2 NCT04216290
  17. Notable: Biological Effects of DS-8201a on · Advanced Cancer Results posted: Nov 17, 2026 National Cancer Institute (NCI)Phase 1 NCT04294628
  18. Notable: Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Recruitment opened National Cancer Institute (NCI)Phase 2/3 NCT07724457
  19. Notable: 000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations Eligibility criteria changed National Cancer Institute (NCI)Phase 1/2 NCT05588141
  20. Minor: Chemoradiotherapy With or Without Atezolizumab · Localized Muscle Invasive Bladder Cancer Primary completion date changed from estimate of Jun 1, 2027 to Jul 23, 2026 National Cancer Institute (NCI)Phase 3 NCT03775265
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-11-16 NCT07937696 A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch… Phase 2 Not Yet Recruiting
2026-11-04 NCT07914855 Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer Phase 2 Not Yet Recruiting
2026-10-29 NCT07902921 STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic… Phase 1/2 Not Yet Recruiting
2026-10-23 NCT07891286 Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children… Phase 2 Not Yet Recruiting

Active trials by phase

Early Phase 1
1
Phase 1
162
Phase 1/2
78
Phase 2
317
Phase 2/3
17
Phase 3
79
Phase 4
3
Not charted: 124 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 50

Get alerts when National Cancer Institute (NCI)'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free